Introduction {#s1}
============

MicroRNAs (MiRNAs) are a family of naturally occurring, small noncoding RNAs of 21--24 nucleotides in length that regulate gene expression by base pairing with target mRNAs at the 3′UTR, leading to mRNA cleavage or translational repression [@pone.0065123-LagosQuintana1], [@pone.0065123-Lau1]. MiRNAs encoded in the genome are transcribed by RNA polymerase II or RNA polymerase III in the nucleus, where they cleaved by Drosha and Dicer sequentially [@pone.0065123-Lee1], [@pone.0065123-Borchert1]. It has been suggested that miRNAs are important post-transcriptional regulators of gene expression that control diverse physiological and pathological processes. Accumulating evidence indicates that aberrant expressions of miRNAs were indicated to involve in tumorigenesis, development and prognosis of many cancers [@pone.0065123-Wienholds1], [@pone.0065123-Chen1], [@pone.0065123-Brennecke1], [@pone.0065123-Cimmino1], [@pone.0065123-Hatfield1].

Single nucleotide polymorphisms (SNPs) were found in most genes, and recently SNPs of miRNAs have been paid much more attention. Studies have reported that miRNA SNPs could alter expressions or functions of miRNAs, and related to cancer risk. Meanwhile, studies have reported polymorphisms in miRNA genes, biogenesis pathway of miRNAs and their target binding sites. Moreover, polymorphisms in miRNA genes could directly influence the expressions and functions of miRNAs. Recently, miR-146aG\>C (rs2910164), miR-196a2C\>T (rs11614913) and miR-499A\>G (rs3746444) were drawed close attention and were expected to demonstrate the association with many cancers [@pone.0065123-Tian1], [@pone.0065123-Min1], [@pone.0065123-Li1], [@pone.0065123-Hu1], [@pone.0065123-Okubo1], [@pone.0065123-Chu1], [@pone.0065123-Dou1], [@pone.0065123-George1]. However, the results were generally inconsistent and inconclusive. Therefore, this meta-analysis focused on these three polymorphisms to deliberate their associations with cancer risk, which have surveyed in many populations. According to the recent studies, consistent conclusions were observed in Caucasian population while conflicting results were found in Asian population [@pone.0065123-Hu1], [@pone.0065123-Xu1], [@pone.0065123-Chen2], [@pone.0065123-Zhu1], [@pone.0065123-Zhou1], [@pone.0065123-Zhang1], [@pone.0065123-Alshatwi1] due to the different countries, the numbers of study population, cancer types. To draw a conclusion of three polymorphisms and cancer risk in Asian population, an analysis of pooled published studies was required. This meta-analysis explored the associations between polymorphisms of three miRNAs and cancer in Asian population.

Materials and Methods {#s2}
=====================

Literature and Inclusion Criteria {#s2a}
---------------------------------

Using the combined words "miR-146a/miR-196a2/miR-499", "cancer" or "carcinoma", "genetic variation" or "polymorphism", a comprehensive systematic bibliographic searching was applied through the medical databases PubMed, EMBASE and Web of Science for all medical published up to October 15th, 2012. In addition, studies were identified by manual search of the reference listed in the retrieved studies. Data from studies were accepted in our meta-analysis only if the study met all of the following criteria: (1) published in English; (2) available cancer risk and miR-146a/miR-499/miR-196a2 polymorphism data related to Asian population; (3) case-control studies; (4) sources of cases and sufficient available data to estimate an odds ratio (OR) with 95% confidence interval (CI); (5) available genotype frequency. Moreover, the studies were eliminated if there are no raw data in the studies, or they are case-only studies, case reports, editorials, and review articles (including meta-analyses).

Data Extraction {#s2b}
---------------

Information was reviewed carefully extracted from all the eligible articles independently by two of the authors (Yeqiong Xu and Ling Gu) according to the inclusion criteria listed above. The characteristics information of enrolled studies was extracted from the study: the first author's last name, year of publications, country of subjects, cancer type, the source of controls, genotyping method, matching numbers of genotyped cases and controls, polymorphism site and *P* for HWE ([Table 1](#pone-0065123-t001){ref-type="table"}). If discrepancies and differences were existed after data collection, discussion was carried out to get consensus.
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###### Characteristics of studies included in the meta-analysis.

![](pone.0065123.t001){#pone-0065123-t001-1}

  Author        Year     Country           Cancer type        Control Source           Method                                                                                                                                                                          Patient                                                                                                                                                                                                                                                                                                         Health                                                                                                                                           Case/Control          Polymorphism site               *P* for HWE
  ------------ ------ -------------- ----------------------- ---------------- ------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- --------------------------------- -----------------------
  Xu            2008      China                HCC                  PB                PCR-RFLP                                                                                                              479 HCC patients were diagnosed histopathologically, lived in Guangzhou or the surrounding regions, mean age (SD) 45.2(12.1)                                                                                                                                                                           504 cancer-free controls were collected in the same period as patients, frequency-matched to the cases on age and sex, mean age (SD) 44.6(11.4)                                                                        479/504                rs29010164                      0.119
  Hu            2008      China           Breast cancer             PB                PCR-RFLP                                                                              1009 newly diagnosed and histopathologically confirmed breast cancer patients from Nanjing, including 998 invasive, 28 ductal carcinoma, and 3 lobular carcinoma, mean age (SD) 51.60(11.08)                                                                                                                                                       1093 cancer-free control women, frequency-matched to the cases on age and residential area, mean age (SD) 51.77(11.19)                                                                                    1009/1093     rs11614913,rs29010164,rs3746444     0.207,0.221,0.057
  Tian          2009      China            Lung cancer              PB                PCR-RFLP                                                                                             1058 lung cancer patients were histopathologically diagnosed, lived in Nanjing, without the restrictions of age, sex, and histology, mean age (SD) 59.78(10.04)                                                                                                 1035 cancer-free controls conducted in Jiangsu Province during the same period as the cases were recruited. The control subjects had no history of cancer and were frequency matched to the cases on age, sex, and residential area, mean age (SD) 59.66(9.83)                1058/1035     rs11614913,rs29010164,rs3746444     0.700,0.853,0.404
  Guo           2010      China         Esophageal cancer           PB                SNPshot                                                                                                   444 ESCC patients were from Chongqing City and the surrounding regions and were histopathologically diagnosed without the restrictions of age and sex                                                                                                                                              468 Cancer-free controls, having no history or family history of cancer and other genetic disease, and were frequency matched to the cases on age, gender, and residential area                                                        444/468                rs29010164                      0.12
  Zeng          2010      China          Gastric cancer             HB                PCR-RFLP                                                                                                  304 gastric cancer patients (mean age 59, age range 51--66) were from Jiangsu Province, and all confirmed by endoscopic biopsy or surgical specimens                                                                                                                                                            304 cancer-free controls (mean age 58, age range 50--66) matched to gastric cancer cases by gender and age, were selected from patients hospitalized                                                                      304/304                rs29010164                      0.122
  Srivastava    2010   North Indian    Gallbladder cancer           PB                PCR-RFLP                                                                                                          230 gallbladder cancer patients were diagnosis and confirmed for all cases by fine needle aspirated cell cytology and histopathology                                                                                                                                                    230 control subjects were healthy adults without a history of cancer, who were randomly selected from general population and were frequency matched to cancer cases on age and gender                                                     230/230      rs11614913,rs29010164,rs3746444     0.068,0.080,0.566
  Xu            2010      China          Prostate cancer            PB                PCR-RFLP                                                                                                                                         251 prostate cancer patients were confirmed by biopsy, lived in Nanjing                                                                                                                                                                                                       280 controls were age-matched, and the subjects were healthy checkup examinees without cancer history and were collected in the same period                                                                          251/280                rs29010164                      0.191
  Chen          2010      China                CRC                  PB                PCR--LDR                                                                                                         126 CRC patients had undergone surgery and been histopat hologically confirmed.The mean age was 57.9.All cases were ethnically Chinese                                                                                                                                                        407 controls were free of disease on health check-up. They were matched with the case patients by age and sex. The mean age was 55.6. All controls were ethnically Chinese                                                           126/407                rs11614913                      0.789
  Li            2010      China                HCC                  HB                PCR-RFLP                                                                                                           310 cirrhosis patients (mean age 49) with HCC served as cases were diagnosed via histopathology. The subjects were all Han Chinese                                                                                                                                                                                            222 cirrhosis patients (mean age 50) without HCC served as controls. The subjects were all Han Chinese                                                                                             310/222                rs11614913                      0.402
  Yoo           2010      Korea            Lung cancer              PB         Melting curve analysis   654 newly diagnosed lung cancer patients included 287 squamous cell carcinomas, 246 adenocarcinomas, 10 large cell carcinomas, and 101 small cell carcinomas. There were no gender, histologic, or stage restrictions, mean age (SD) 61.1(9.0). All patients were ethnic Koreans who resided in Daegu City or the surrounding regions                                             640 control subjects were frequency-matched to the cases based on gender and age, mean age (SD) 60.5(9.4). All controls were ethnic Koreans who resided in Daegu City or the surrounding regions                                                654/640                rs11614913                      0.126
  Dou           2010      China              Glioma                 PB                PCR--LDR                                                          670 newly diagnosed glioma cancer patients confirmed via histopathology, including 246 astrocytomas, 204 glioblastoma, 193 other gliomas. All the subjects were Han Chinese origin. Among them, 643 cases were genotyped successfully                                                                                          680 cancer-free controls were frequency matched to the cases with the same age, sex, and residence area. All the subjects were Han Chinese origin.Among them, 656 controls were genotyped successfully                                             643/656                rs11614913                      0.119
  Qi            2010      China                HCC                  PB                PCR--LDR                                                                                        361 HCC patients (mean age 49) with chronic HBV infection were designated as cases. The diagnosis of HCC was histopathologically confirmed, All subjects were Han Chinese                                                                                                                                                                            391 healthy volunteers (mean age 35) served as healthy controls. All subjects were Han Chinese                                                                                                 361/391                rs11614913                      0.869
  Peng          2010      China          Gastric cancer             PB                PCR-RFLP                                                                                            213 gastric cancer were inpatients newly diagnosed and histopathologically confirmed. The subjects in this study were unrelated Han Chinese, mean age (SD) 58(12)                                                                                                                        213 cancer-free controls had no current or previous diagnosis of cancer and were frequency matched to cases on age and gender. The subjects in this study were unrelated Han Chinese, mean age (SD) 58.3(11.8)                                         213/213                rs11614913                      0.936
  Zhou          2011      China                HCC                  PB                PCR-RFLP                                                                                                             186 patients with primary liver cancer were diagnosed either by histopathologic or imaging evidence, mean age (SD) 52.10(15.20)                                                                                                                                                                               483 healthy individuals undergoing routine medical examination without any medical illness, matched with patients by age and gender                                                                              186/483           rs29010164,rs3746444              0.056,0.100
  Yue           2011      China          Cervical cancer            PB                PCR-RFLP                                                                                             447 cervical cancer patients were newly diagnosed and histologically confirmed. All subjects were genetically-unrelated Han Chinese, mean age (SD) 46.38(8.98)                                                                                       443 cancer-free controls consisted of women in good health and with no malignancy history. They were frequency-matched to the cases by age, with people who were being recruited during the same time. All subjects were genetically-unrelated Han Chinese, mean age (SD) 46.38(8.98)     447/443                rs29010164                      0.285
  Mittal        2011   North India       Bladder cancer             PB                PCR-RFLP                                                                                                                 212 histologically confirmed patients with UBC (mean age 59.0 years; 187 men and 25 women) were unrelated North Indian.                                                                                                                                   250 healthy and genetically unrelated were recruited as the control (mean age 57.8 years, 215 men and 35 women). All the controls were age, sex matched, of similar ethnicity, and had no evidence of malignancy or chronic disease                              212/250      rs11614913,rs29010164,rs3746444   **0.003,0.007,0.020**
  Zhou          2011      China          Cervical cancer            PB                PCR-RFLP                              226 unrelated female patients ranging in age from 23 to 75, mean (SD) 44.96 (9.48). The diagnosis of CSCC was confirmed in all cases by histological examination of tissue from biopsy or resected specimens. All subjects were Han population living in Sichuan province of southwest China                                                                                        309 healthy women was selected randomly from a routine health survey in the same hospital according to the age distribution of individuals with CSCC                                                                      226/309      rs11614913,rs29010164,rs3746444   0.077,0.060,**0.005**
  Okubo         2011      Japan          Gastric cancer             HB                PCR-RFLP                                                                                                         552 gastric cancer patients was diagnosed histologically and was classified according to Lauren's classification, mean(SD ) 64.4(11.2)                                                                                                                            697 non-cancer subjects had no evidence of GC by upper gastroscopy, 214 subjects were diagnosed as having ulcer diseases including 141 GU and 73 DU, while 483 subjects were diagnosed as non-ulcer subjects, mean(SD ) 61.0(13.5)                               552/697      rs11614913,rs29010164,rs3746444   0.510,0.278,**0.048**
  Hishida       2011      Japan          Gastric cancer             HB                PCR-CTPP                                                                                                                                            583 of the cases diagnosed as gastric cancer, mean(SD) 58.8(10.5)                                                                                                                                                                                                                          1637 cancer-free outpatients (controls) were age- and sex-frequency matched with cases, mean(SD) 58.7(10.6)                                                                                          583/1637               rs29010164                      0.738
  George        2011   North Indian      Prostate cancer            PB                PCR-RFLP                                                                                                                                     159 prostate cancer patients were histologically confirmed, mean(SD) 66.6(6.22)                                                                                                                                                                                                                           230 controls matched each case patient in age (65.8±7.29) from a population of healthy men                                                                                                   159/230      rs11614913,rs29010164,rs3746444   **0.002,0.002**,0.073
  Min           2011      Korea                CRC                  PB                PCR-RFLP                                                                                                  446 CRC patients included 147 proximal colon cancer, 104 distal colon cancer, 185 rectal cancer, 11 ixed colorectal cancer, mean age(SD) 61.89(12.35)                                                                                                                                                                    502 controls randomly selected following a heath screening which were age and gender matched with cases, mean age(SD) 61.74(12.11)                                                                               446/502      rs11614913,rs29010164,rs3746444     0.633,0.443,0.453
  Zhu           2011      China                CRC                  PB                 Taqman                                                                                                                               573 newly diagnosed CRC patients were histopathologically confirmed, mean age(SD) 60.3(12.5)                                                                                                                                                                        588 cancer-free controls were genetically unrelated to the cases without individual history of cancer, and frequency matched to patients based on sex and age, mean age(SD) 59.3(9.8)                                                     573/588                rs11614913                      0.79
  Hong          2011      Korea            Lung cancer              HB                 Taqman                                                                                                                           406 lung cancer patients were histopathologically diagnosed as having NSCLC, mean age(SD) 67.3(10.2)                                                                                                                                                                               428 cancer-free controls were recruited from among the residents of Busan city, and frequency matched to patients based on sex and age, mean age(SD) 63.2(10.2)                                                                406/428                rs11614913                      0.163
  Zhan          2011      China                CRC                  HB                PCR-RFLP                                                                                                   252 CRC patients (mean age 54.8) were in-patien ts with newly diagnosed and histopathologically confirmed. All subjects were unrelated Han Chinese                                                                                                                                          543 cancer-free control subjects (mean age 53.2) had no current or previous diagnosis of cancer and were frequently age or gender matched to cases. All subjects were unrelated Han Chinese                                                  252/543                rs11614913                      0.849
  Zhang         2011      China           Breast cancer             PB                PCR-RFLP                                                                                            252 breast cancer women were recruited without any restrictions on age, sex or disease histology, and were collected in Jiashan County, mean age(SD) 54.66(11.18)                                                                                                                                                            248 controls were enrolled from the cancer-free population matched with cases by age, sex and residence area, mean age(SD) 54.51(11.41)                                                                            252/248                rs11614913                      0.893
  Xiang         2012      China                HCC                  PB                PCR-RFLP                                                                                              100 HCC patients without any other types of liver diseases histopathologically confirmed, including 27 without HBV and 73 with HBV, mean age(SD) 48.55(9.29)                                                                                                                                                                                                100 healthy controls were matched with age, mean age(SD) 45.12(15.82)                                                                                                             100/100           rs29010164,rs3746444              0.506,0.284
  Kim           2012      Korea                HCC                  PB                PCR-RFLP                                                                                            159 HCC patients were included. The clinical stage of HCC was evaluated on the basis of the TNM classification and OKUDA stage system, mean age(SD) 56.06(11.02)                                                                                                                                 201 controls selected from health screening program participants to exclude those with a history of cancer and other medical diseases, were matched with age and sex, mean age(SD) 53.58(11.17)                                                159/201      rs11614913,rs29010164,rs3746444     0.356,0.190,0.278
  Zhou          2012      China          Gastric cancer             HB                 TaqMan                                                                               750 gastric patients from Nanjing and 936 patients from Yixing served as cases. All the patients were newly diagnosed with histopathologically confirmed. All subjects are ethnic Han Chinese                                                                                                                                       835 healthy from Nanjing and 1060 healthy from Yixing served as controls, were age- and sex- matched with cases. All subjects are ethnic Han Chinese                                                                     1686/1895               rs29010164                      0.641
  Lung          2012      China       Nasopharyngeal cancer         PB         Melting curve analysis                                                                                                                              233 nasopharyngeal cancer patients were from HongKong, mean age(SD) 51.3(11.3)                                                                                                                                                                                                    173 sex- and age- matched healthy selected from HongKong. Participants in all control groups had no cancer history, mean age(SD) 49.5(10.0)                                                                          233/173                rs29010164                      0.106
  Alshatwi      2012   Saudi Arabia       Breast cancer             PB                 TaqMan                                                                                                                          100 breast cancer patients included 58 premenopausal (mean age 37.5) and postmenopausal (mean age 61.2)                                                                                                                                                                                                                                       100 healthy controls were matched with age                                                                                                                           100/100      rs11614913,rs29010164,rs3746444   **0.032**,0.051,0.227
  Chu           2012      China            Oral cancer              HB                PCR-RFLP                                                                                                                                                      470 male patients from Taiwan were included.                                                                                                                                                                                                         425 male controls matched with age were enrolled from the physical examination in the hospitals as cases, had neither self reported history of cancer of any sites                                                               470/425      rs11614913,rs29010164,rs3746444     0.686,0.939,0.975

HCC: hepatocellular carcinoma; CRC: colorectal cancer; HB: hospital based; PB: population based; PCR-RFLP: polymerase chain reaction--restriction fragment length polymorphism; PCR-CTPP: polymerase chain reaction with confronting two-pair primers; PCR-LDR: ligation detection reaction; HWE: Hardy-Weinberg equilibrium.

Statistical Analysis {#s2c}
--------------------

The strength of association between the three SNPs and cancer risk was assessed by odds ratios (ORs) with 95% confidence intervals (CIs). The pooled ORs were estimated for dominant model, recessive model, homozygote comparison, heterozygote comparison and allelic comparison, respectively. Stratified analyses were also performed by cancer type (HCC, CRC, cervical cancer, prostate cancer, breast cancer, gastric cancer, lung cancer, and other cancers group which combined the cancer types containing less than two individual studies), country (China, Korea, Japan, North India and other countries group which combined the countries containing less than two individual studies) source of control and genotyping method. Heterogeneity across the studies was evaluated by using the Chi-square test based Q-statistic test, and it was considered significant when *P~heterogeneity~* (*P* ~h~) \<0.05. The data were combined using both fixed-effects (the Mantel-Haenszel method) and random effects (the DerSimonian and Laird method) models. A random-effect model was employed when heterogeneity existed [@pone.0065123-Srivastava1]--[@pone.0065123-Kim1], Otherwise, the fixed-effect model was employed to pool the results [@pone.0065123-Duval1]. Moreover, to assess the stability of the results, a sensitivity analysis was performed. Publication bias was checked graphically by using funnel plots and statistically using the Egger\'s linear regression test. For the controls of each study, the genotype frequencies of the three polymorphisms of miRNA were assessed for Hardy-Weinberg equilibrium using a web-based program (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). All statistical tests were performed with STATA 10.0 and all the *P* values were two-sided.

Results {#s3}
=======

Characteristics of Studies {#s3a}
--------------------------

This study enrolled 31 eligible papers ([Figure 1](#pone-0065123-g001){ref-type="fig"}) according to the inclusion criteria. For rs2910164 polymorphism, 21 studies with available data were enrolled in the pooled analysis. These studies consisted of China (13 studies), Korea (2 studies), North India (3 studies) and Japan (2 studies) related to HCC (4 studies), gastric cancer (4 studies), cervical cancer (2 studies), prostate cancer (2 studies), breast cancer (2 studies) and other cancers (7 studies). In addition, the controls of most studies were population-based, and the main genotyping method was PCR-RFLP ([Table 1](#pone-0065123-t001){ref-type="table"}).

![Flow chart of studies identified according to inclusion and exclusion criteria.](pone.0065123.g001){#pone-0065123-g001}

For rs11614913 polymorphism, 21 studies provided available data, which were classified into CRC (4 studies), HCC (3 studies), breast cancer (3 studies), lung cancer (3 studies), gastric cancer (2 studies) and other cancers (6 studies). Meanwhile, these studies with data of 12 studies of Chinese population, 4 studies of Korean population, 3 studies of North Indian population and 2 studies of other countries. To analyze polymorphisms, genotyping by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were performed by the most studies, in which 16 were population-based and 5 were hospital-based ([Table 1](#pone-0065123-t001){ref-type="table"}).

For rs3746444 polymorphism, 13 studies covered China (6 studies), Korea (2 studies), North India (3 studies) and other countries (2 studies) related to HCC (3 studies), breast cancer (2 studies) and other cancers (8 studies) were included in the pooled analysis. What\'s more, these studies contained 11 of population-based controls and 2 of hospital-based controls.

Main Results {#s3b}
------------

For rs2910164 polymorphism, results of pooled analysis revealed significantly decreased risk was observed for the the comparison of homozygote model (CC vs GG: OR = 0.83, 95% CI: 0.70--0.99, *P* ~h~ = 0.000), heterozygote model (GC vs GG: OR = 0.91, 95% CI: 0.85--0.98, *P* ~h~ = 0.160) ([Figure 2](#pone-0065123-g002){ref-type="fig"}) and dominant model (CC+GC vs GG: OR = 0.89, 95% CI: 0.80--1.00, *Z* = 2.06, *P* = 0.040, *P* ~h~ = 0.004). Cancer subgroup analysis revealed an obvious decreased risk was found in cervical cancer for all four comparison models (CC vs GG: OR = 0.50, 95% CI: 0.37--0.68, *P* ~h~ = 0.814; GC vs GG: OR = 0.72, 95% CI: 0.55--0.95, *P* ~h~ = 0.254; CC+GC vs GG: OR = 0.63, 95% CI: 0.49--0.82, *P* ~h~ = 0.382; CC vs GG+GC: OR = 0.65, 95% CI: 0.52--0.82, *P* ~h~ = 0.359). Similarly, decreased cancer risk was observed when compared of homozygote model and recessive model in prostate cancer (CC vs GG: OR = 0.54, 95% CI: 0.34--0.87, *P* ~h~ = 0.425; CC vs GG+GC: OR = 0.65, 95% CI: 0.44--0.96, *P* ~h~ = 0.699). Moreover, a decreased risk was observed in HCC for the comparison of homozygote model and dominant model (CC vs GG: OR = 0.75, 95% CI: 0.57--0.98, *P* ~h~ = 0.213; CC+GC vs GG: OR = 0.77, 95% CI: 0.61--0.98, *P* ~h~ = 0.284) as well. Country subgroup analysis revealed that rs2910164 C allele was associated with a decreased risk of cancer in Chinese population (CC vs GG: OR = 0.73, 95% CI: 0.60--0.88, *P* ~h~ = 0.000; GC vs GG: OR = 0.87, 95% CI: 0.80--0.94, *P* ~h~ = 0.248; CC+GC vs GG: OR = 0.81, 95% CI: 0.72--0.92, *P* ~h~ = 0.032; CC vs GG+GC: OR = 0.83, 95% CI: 0.71--0.97, *P* ~h~ = 0.000). Moreover, a significantly decreased risk was found for the comparison of homozygote model (CC vs GG: OR = 0.79, 95% CI: 0.64--0.98, *P* ~h~ = 0.001), heterozygote model (GC vs GG: OR = 0.90, 95% CI: 0.83--0.99, *P* ~h~ = 0.232) and dominant model (CC+GC vs GG: OR = 0.86, 95% CI: 0.75--0.98, *P* ~h~ = 0.021) in population-based controls. Finally, genotyping method subgroup analysis revealed a decreased cancer risk determined by Taqman in all four comparion models (CC vs GG: OR = 0.70, 95% CI: 0.58--0.85, *P* ~h~ = 0.450; GC vs GG: OR = 0.92, 95% CI: 0.85--0.98, *P* ~h~ = 0.467; CC+GC vs GG: OR = 0.79, 95% CI: 0.69--0.91, *P* ~h~ = 0.479; CC vs GG+GC: OR = 0.79, 95% CI: 0.67--0.93, *P* ~h~ = 0.667), as summarized in [Table 2](#pone-0065123-t002){ref-type="table"}.

![Forest plots of effect estimates for rs2910164 stratified by country (GC vs GG).\
For each studies, the estimate of OR and its 95% CI is plotted with a *box* and a *horizontal line*. *Filled diamond* pooled OR and its 95% CI.](pone.0065123.g002){#pone-0065123-g002}
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###### Stratified analyses of the miR-146aG\>C (rs2910164) polymorphism and cancer risk.

![](pone.0065123.t002){#pone-0065123-t002-2}

  Variables             n[a](#nt103){ref-type="table-fn"}                         CC vs GG                         GC vs GG   CC+GC vs GG       CC vs GG+GC       C allele vs G allele                                                                                                                                                                                                                    
  -------------------- ----------------------------------- ------------------------------------------------------ ---------- ------------- --------------------- ---------------------- ------ ------------------------------------------------------ ------- ------ ------------------------------------------------------ ------- ------ ------------------------------------------------------ ------- ------
  Total                                21                   **0.83(0.70,0.99)** [c](#nt105){ref-type="table-fn"}    0.000        65.8       **0.91(0.85,0.98)**          0.160           23.6   **0.89(0.80,1.00)** [c](#nt105){ref-type="table-fn"}   0.004   50.7     0.89(0.79,1.01)[c](#nt105){ref-type="table-fn"}      0.000   65.4   **0.92(0.85,1.00)** [c](#nt105){ref-type="table-fn"}   0.000   69.3
  Cancer type                                                                                                                                                                                                                                                                                                                                                                                             
  HCC                                   4                                   **0.75(0.57,0.98)**                     0.213        33.1         0.79(0.61,1.02)            0.343           10.0                   **0.77(0.61,0.98)**                    0.284   21.0                     0.88(0.73,1.05)                      0.234   29.7                   **0.88(0.78,1.00)**                    0.245   27.8
  Cervical cancer                       2                                   **0.50(0.37,0.68)**                     0.814         0.0       **0.72(0.55,0.95)**          0.254           23.1                   **0.63(0.49,0.82)**                    0.382   0.0                    **0.65(0.52,0.82)**                    0.359   0.0                    **0.72(0.62,0.84)**                    0.796   0.0
  Prostate cancer                       2                                   **0.54(0.34,0.87)**                     0.425         0.0         0.91(0.67,1.22)            0.131           56.1                     0.85(0.64,1.13)                      0.062   71.4                   **0.65(0.44,0.96)**                    0.699   0.0                      0.83(0.69,1.01)                      0.071   69.3
  Breast cancer                         2                                     1.00(0.77,1.29)                       0.708         0.0         1.03(0.81,1.31)            0.619           0.0                      1.02(0.81,1.28)                      0.662   0.0                      0.97(0.81,1.15)                      0.745   0.0                      0.99(0.88,1.11)                      0.854   0.0
  Gastric cancer                        4                     0.92(0.63,1.34)[c](#nt105){ref-type="table-fn"}       0.000        84.1         0.91(0.81,1.02)            0.136           45.8     0.96(0.74,1.24)[c](#nt105){ref-type="table-fn"}      0.011   73.1     0.92(0.70,1.21)[c](#nt105){ref-type="table-fn"}      0.000   83.5     0.95(0.78,1.16)[c](#nt105){ref-type="table-fn"}      0.000   86.4
  Other cancers                         7                     0.97(0.72,1.32)[c](#nt105){ref-type="table-fn"}       0.030        57.0         0.96(0.85,1.09)            0.256           22.7                     0.96(0.86,1.08)                      0.119   40.8     1.00(0.75,1.34)[c](#nt105){ref-type="table-fn"}      0.002   71.6     0.99(0.85,1.14)[c](#nt105){ref-type="table-fn"}      0.004   69.1
  Country                                                                                                                                                                                                                                                                                                                                                                                                 
  China                                13                   **0.73(0.60,0.88)** [c](#nt105){ref-type="table-fn"}    0.000        66.7       **0.87(0.80,0.94)**          0.248           19.3   **0.81(0.72,0.92)** [c](#nt105){ref-type="table-fn"}   0.032   46.6   **0.83(0.71,0.97)** [c](#nt105){ref-type="table-fn"}   0.000   70.5   **0.87(0.79,0.95)** [c](#nt105){ref-type="table-fn"}   0.000   70.3
  Korea                                 2                                     0.98(0.69,1.39)                       0.367         0.0         1.14(0.81,1.60)            0.435           0.0                      1.07(0.77,1.48)                      0.380   0.0                      0.88(0.70,1.11)                      0.658   0.0                      0.96(0.82,1.12)                      0.491   0.0
  North India                           3                                     1.30(0.69,2.48)                       0.382         0.0         1.01(0.80,1.26)            0.246           28.6                     1.03(0.82,1.28)                      0.195   38.7                     1.29(0.68,2.44)                      0.441   0.0                      1.04(0.87,1.25)                      0.204   37.1
  Japan                                 2                                     1.21(0.97,1.52)                       0.069        69.8         1.09(0.87,1.35)            0.272           17.2                     1.15(0.93,1.41)                      0.123   57.9                     1.14(0.98,1.32)                      0.130   56.4                     1.11(1.00,1.23)                      0.058   72.3
  Source of controls                                                                                                                                                                                                                                                                                                                                                                                      
  Population based                     16                   **0.79(0.64,0.98)** [c](#nt105){ref-type="table-fn"}    0.001        61.4       **0.90(0.83,0.99)**          0.232           19.4   **0.86(0.75,0.98)** [c](#nt105){ref-type="table-fn"}   0.021   46.6     0.88(0.76,1.03)[c](#nt105){ref-type="table-fn"}      0.001   61.5     0.91(0.83,1.00)[c](#nt105){ref-type="table-fn"}      0.000   65.1
  Hospital based                        5                     0.93(0.68,1.27)[c](#nt105){ref-type="table-fn"}       0.001        79.3         0.93(0.83,1.04)            0.114           46.4     0.98(0.78,1.23)[c](#nt105){ref-type="table-fn"}      0.014   67.8     0.91(0.73,1.13)[c](#nt105){ref-type="table-fn"}      0.001   78.5     0.95(0.81,1.12)[c](#nt105){ref-type="table-fn"}      0.000   81.9
  Genotyping method                                                                                                                                                                                                                                                                                                                                                                                       
  PCR-RFLP                             16                     0.84(0.69,1.03)[c](#nt105){ref-type="table-fn"}       0.000        65.6         0.96(0.88,1.05)            0.153           26.9     0.91(0.80,1.04)[c](#nt105){ref-type="table-fn"}      0.007   52.9     0.88(0.77,1.00)[c](#nt105){ref-type="table-fn"}      0.002   58.7     0.92(0.84,1.01)[c](#nt105){ref-type="table-fn"}      0.000   66.7
  Taqman                                2                                   **0.70(0.58,0.85)**                     0.450         0.0       **0.92(0.85,0.98)**          0.467           0.0                    **0.79(0.69,0.91)**                    0.479   0.0                    **0.79(0.67,0.93)**                    0.667   0.0                    **0.84(0.76,0.92)**                    0.570   0.0
  Other methods                         3                     0.85(0.45,1.62)[c](#nt105){ref-type="table-fn"}       0.008        79.5         0.85(0.70,1.02)            0.441           0.0                      0.85(0.71,1.01)                      0.160   45.5     1.00(0.55,1.80)[c](#nt105){ref-type="table-fn"}      0.001   86.7     1.00(0.73,1.37)[c](#nt105){ref-type="table-fn"}      0.001   86.0

HCC: hepatocellular carcinoma; PCR-RFLP: polymerase chain reaction--restriction fragment length polymorphism.

Number of included studies.

*P* value of *Q* test for heterogeneity test.

Random-effect model was used when P value for heterogeneity \<0.05; otherwise, fixed-effect model was used.

Statistically significant results were in bold.

For rs11614913 polymorphism, decreased risk associations were observed in the overall pooled analysis for the comparison of homozygote model (TT vs CC: OR = 0.84, 95% CI: 0.74--0.95, *P* ~h~ = 0.029) and recessive model (TT vs CC+CT: OR = 0.86, 95% CI: 0.80--0.92, *P* ~h~ = 0.389) ([Figure 3](#pone-0065123-g003){ref-type="fig"}). Cancer types subgroup analysis revealed a significant association in the comparison of homozygote model (TT vs CC: OR = 0.70, 95% CI: 0.57--0.85, *P* ~h~ = 0.284), heterozygote model (CT vs CC: OR = 0.81, 95% CI: 0.68--0.97, *P* ~h~ = 0.367), dominant model (TT+CT vs CC: OR = 0.77, 95% CI: 0.65--0.91, *P* ~h~ = 0.377) and recessive model (TT vs CC+CT: OR = 0.80, 95% CI: 0.69--0.94, *P* ~h~ = 0.198) in colorectal cancer. Similarly, a decreased risk was observed for the comparison of homozygote model (TT vs CC: OR = 0.77, 95% CI: 0.65--0.91, *P* ~h~ = 0.895), dominant model (TT+CT vs CC: OR = 0.85, 95% CI: 0.74--0.98, *P* ~h~ = 0.289) and recessive model (TT vs CC+CT: OR = 0.83, 95% CI: 0.73--0.95, *P* ~h~ = 0.281) in lung cancer and homozygote model (TT vs CC: OR = 0.79, 95% CI: 0.63--0.99, *P* ~h~ = 0.127) in breast cancer. In contrast, an increased risk was observed in other cancers (CT vs CC: OR = 1.49, 95% CI: 1.28--1.74, *P* ~h~ = 0.178; TT+CT vs CC: OR = 1.39, 95% CI: 1.20--1.61, *P* ~h~ = 0.226). Subgroup analysis by country revealed a decreased risk for the comparison of recessive model in China (TT vs CC+CT: OR = 0.87, 95% CI: 0.80--0.94, *P* ~h~ = 0.252) and Korea (OR = 0.83, 95% CI: 0.72--0.97, *P* ~h~ = 0.327). In addition, the decreased risk was also observed for comparison of homozygote model (TT vs CC: OR = 0.77, 95% CI: 0.64--0.93, *P* ~h~ = 0.616) and dominant model (TT+CT vs CC: OR = 0.84, 95% CI: 0.72--0.98, *P* ~h~ = 0.162) in Korea. However, an increased risk was observed in North India (CT vs CC: OR = 1.53, 95% CI: 1.22--1.93, *P* ~h~ = 0.832; TT +CT vs CC: OR = 1.43, 95% CI: 1.15--1.79, *P* ~h~ = 0.796). Subgroup analysis by the source of control revealed significant decrease risk for the comparison of recessive model not only in the hospital-population based controls (TT vs CC+CT: OR = 0.79, 95% CI: 0.69--0.90, *P* ~h~ = 0.295) but also in population-based controls (TT vs CC+CT: OR = 0.88, 95% CI: 0.81--0.95, *P* ~h~ = 0.509), and a decreased risk for the comparison of homozygote model (TT vs CC: OR = 0.82, 95% CI: 0.74--0.91, *P* ~h~ = 0.226) was revealed in population-based controls as well. Subgroup analysis determined by genotyping method showed a significant association between the polymorphism and cancer risk in both PCR-RFLP and Taqman group for the comparison of homozygote model (TT vs CC: OR = 0.81, 95% CI: 0.69--0.96, *P* ~h~ = 0.044; OR = 0.71, 95% CI: 0.55--0.91, *P* ~h~ = 0.740, respectively) and recessive model (TT vs CC+CT: OR = 0.87, 95% CI: 0.80--0.94, *P* ~h~ = 0.444; OR = 0.69, 95% CI: 0.57--0.85, *P* ~h~ = 0.903, respectively), as summarized in [Table 3](#pone-0065123-t003){ref-type="table"}.

![Forest plots of effect estimates for rs11614913 stratified by country (TT vs CC+CT).\
For each studies, the estimate of OR and its 95% CI is plotted with a *box* and a *horizontal line*. *Filled diamond* pooled OR and its 95% CI.](pone.0065123.g003){#pone-0065123-g003}

10.1371/journal.pone.0065123.t003

###### Stratified analyses of the miR-196a2C\>T (rs11614913) polymorphism and cancer risk.

![](pone.0065123.t003){#pone-0065123-t003-3}

  Variables             n[a](#nt108){ref-type="table-fn"}                         TT vs CC                         CT vs CC   TT+CT vs CC                     TT vs CC+CT                     T allele vs C allele                                                                                                                                                                         
  -------------------- ----------------------------------- ------------------------------------------------------ ---------- ------------- ------------------------------------------------- ---------------------- ------ ------------------------------------------------- ------- ------ --------------------- ------- ------ ------------------------------------------------- ------- ------
  Total                                21                   **0.84(0.74,0.95)** [c](#nt110){ref-type="table-fn"}    0.029        40.4       1.05(0.92,1.20)[c](#nt110){ref-type="table-fn"}          0.000           66.5   1.00(0.88,1.14)[c](#nt110){ref-type="table-fn"}   0.000   66.9   **0.86(0.80,0.92)**   0.389   5.4    0.94(0.88,1.00)[c](#nt110){ref-type="table-fn"}   0.007   48.3
  Cancer type                                                                                                                                                                                                                                                                                                                                                                              
  CRC                                   4                                   **0.70(0.57,0.85)**                     0.284        21.1                     **0.81(0.68,0.97)**                        0.367           5.2                  **0.77(0.65,0.91)**                 0.377   3.1    **0.80(0.69,0.94)**   0.198   35.7                 **0.84(0.76,0.92)**                 0.281   21.6
  HCC                                   3                                     0.89(0.67,1.17)                       0.088        58.9                       0.95(0.74,1.21)                          0.643           0.0                    0.92(0.73,1.17)                   0.277   22.2     0.92(0.74,1.14)     0.113   54.1                   0.94(0.82,1.08)                   0.069   62.5
  Breast cancer                         3                                   **0.79(0.63,0.99)**                     0.127        51.5                       0.96(0.78,1.17)                          0.059           64.6   1.18(0.68,2.03)[c](#nt110){ref-type="table-fn"}   0.028   72.0     0.89(0.75,1.04)     0.114   53.9   1.05(0.78,1.40)[c](#nt110){ref-type="table-fn"}   0.028   72.1
  Gastric cancer                        2                                     0.80(0.61,1.06)                       0.306         4.5                       0.84(0.65,1.08)                          0.163           48.5                   0.82(0.65,1.04)                   0.162   48.8     0.89(0.72,1.11)     0.698   0.0                    0.89(0.78,1.02)                   0.230   30.5
  Lung cancer                           3                                   **0.77(0.65,0.91)**                     0.895         0.0                       0.90(0.77,1.04)                          0.098           57.0                 **0.85(0.74,0.98)**                 0.289   19.4   **0.83(0.73,0.95)**   0.281   21.3                 **0.87(0.80,0.95)**                 0.854   0.0
  Other cancers                         6                                     1.12(0.91,1.38)                       0.238        26.2                     **1.49(1.28,1.74)**                        0.178           34.4                 **1.39(1.20,1.61)**                 0.226   27.8     0.87(0.75,1.02)     0.624   0.0                    1.08(0.99,1.19)                   0.752   0.0
  Country                                                                                                                                                                                                                                                                                                                                                                                  
  China                                12                     0.87(0.72,1.05)[c](#nt110){ref-type="table-fn"}       0.002        62.8       0.99(0.83,1.18)[c](#nt110){ref-type="table-fn"}          0.001           66.4   0.94(0.79,1.12)[c](#nt110){ref-type="table-fn"}   0.000   69.0   **0.87(0.80,0.94)**   0.252   19.5   0.92(0.85,1.00)[c](#nt110){ref-type="table-fn"}   0.007   57.5
  Korea                                 4                                   **0.77(0.64,0.93)**                     0.616         0.0                       0.89(0.75,1.05)                          0.053           60.9                 **0.84(0.72,0.98)**                 0.162   41.6   **0.83(0.72,0.97)**   0.327   13.2                 **0.87(0.79,0.96)**                 0.608   0.0
  North India                           3                                     0.74(0.44,1.26)                       0.571         0.0                     **1.53(1.22,1.93)**                        0.832           0.0                  **1.43(1.15,1.79)**                 0.796   0.0      0.61(0.36,1.02)     0.438   0.0                    1.17(0.99,1.38)                   0.880   0.0
  Other countries                       2                                     0.87(0.63,1.20)                       0.749         0.0                       1.07(0.82,1.40)                          0.093           64.6                   1.03(0.80,1.33)                   0.096   63.8     0.90(0.71,1.15)     0.481   0.0                    0.97(0.84,1.13)                   0.236   28.9
  Source of controls                                                                                                                                                                                                                                                                                                                                                                       
  Population based                     16                                   **0.82(0.74,0.91)**                     0.226        20.0       1.03(0.89,1.20)[c](#nt110){ref-type="table-fn"}          0.000           63.8   1.00(0.86,1.15)[c](#nt110){ref-type="table-fn"}   0.000   64.0   **0.88(0.81,0.95)**   0.509   0.0    0.96(0.89,1.03)[c](#nt110){ref-type="table-fn"}   0.028   44.6
  Hospital based                        5                     0.82(0.58,1.16)[c](#nt110){ref-type="table-fn"}       0.005        72.9       1.10(0.78,1.53)[c](#nt110){ref-type="table-fn"}          0.002           76.3   0.99(0.71,1.37)[c](#nt110){ref-type="table-fn"}   0.001   78.2   **0.79(0.69,0.90)**   0.295   18.8   0.89(0.77,1.03)[c](#nt110){ref-type="table-fn"}   0.024   64.5
  Genotyping method                                                                                                                                                                                                                                                                                                                                                                        
  PCR-RFLP                             14                   **0.81(0.69,0.96)** [c](#nt110){ref-type="table-fn"}    0.044        42.9       1.02(0.85,1.23)[c](#nt110){ref-type="table-fn"}          0.000           71.8   0.98(0.82,1.17)[c](#nt110){ref-type="table-fn"}   0.000   72.0   **0.87(0.80,0.94)**   0.444   0.3    0.94(0.87,1.02)[c](#nt110){ref-type="table-fn"}   0.009   53.4
  Taqman                                3                                   **0.71(0.55,0.91)**                     0.740         0.0                       1.09(0.89,1.35)                          0.099           56.7                   0.97(0.80,1.18)                   0.080   60.5   **0.69(0.57,0.85)**   0.903   0.0                  **0.87(0.77,0.98)**                 0.191   39.6
  PCR--LDR                              3                                     1.14(0.91,1.44)                       0.972         0.0                       1.23(1.00,1.51)                          0.287           19.8                   1.19(0.98,1.45)                   0.517   0.0      0.98(0.82,1.16)     0.576   0.0                    1.05(0.94,1.18)                   0.994   0.0

CRC: colorectal cancer; HCC: hepatocellular carcinoma; PCR-RFLP: polymerase chain reaction--restriction fragment length polymorphism; PCR-LDR: ligation detection reaction.

Number of included studies.

*P* value of *Q* test for heterogeneity test.

Random-effect model was used when P value for heterogeneity \<0.05; otherwise, fixed-effect model was used.

Statistically significant results were in bold.

For rs3746444 polymorphism, an increased risk was revealed for the comparison of homozygote model (GG vs AA: OR = 1.25, 95% CI: 1.03--1.52, *P* ~h~ = 0.073), heterozygote model (GA vs AA: OR = 1.28, 95% CI: 1.08--1.53, *P* ~h~ = 0.000) and dominant model (GG+GA vs AA: OR = 1.27, 95% CI: 1.08--1.50, *P* ~h~ = 0.000) ([Figure 4](#pone-0065123-g004){ref-type="fig"}) in the overall analysis. In the stratified analysis by cancer type, an increased risk was observed in breast cancer for the comparison of dominant model (GG+GA vs AA: OR = 1.31, 95% CI: 1.09--1.57, *P* ~h~ = 0.182). Meanwhile, an increased risk was also found in other cancers (GA vs AA: OR = 1.32, 95% CI: 1.05--1.67, *P* ~h~ = 0.000; GG+GA vs AA: OR = 1.29, 95% CI: 1.05--1.59, *P* ~h~ = 0.001). In addition, sesults of subgroup analysis of country revealed increased cancer risk in China (GA vs AA: OR = 1.36, 95% CI: 1.06--1.75, *P* ~h~ = 0.002; GG+GA vs AA: OR = 1.40, 95% CI: 1.08--1.82, *P* ~h~ = 0.000; GG vs AA+GA: OR = 1.41, 95% CI: 1.06--1.87, *P* ~h~ = 0.050) and North India (GG+GA vs AA: OR = 1.33, 95% CI: 1.07--1.66, *P* ~h~ = 0.150). Similarly, an increased cancer risk association was observed in the subgroup analysis of source of controls. Subgroup analysis of population-based controls group showed the increased cancer risk for the comparison of heterozygote model (GA vs AA: OR = 1.27, 95% CI: 1.05--1.54, *P* ~h~ = 0.000) and dominant model (GG+GA vs AA: OR = 1.24, 95% CI: 1.04--1.47, *P* ~h~ = 0.002). Furthermore, subgroup analysis of hospital-based controls group showed the increased cancer risk for the comparison of homozygote model (GG vs AA: OR = 1.70, 95% CI: 1.09--2.67, *P* ~h~ = 0.121) and recessive model (GG vs AA+GA: OR = 1.67, 95% CI: 1.07--2.61, *P* ~h~ = 0.176), as summarized in [Table 4](#pone-0065123-t004){ref-type="table"}.

![Forest plots of effect estimates for rs3746444 stratified by country (GG+GA vs AA).\
For each studies, the estimate of OR and its 95% CI is plotted with a *box* and a *horizontal line*. *Filled diamond* pooled OR and its 95% CI.](pone.0065123.g004){#pone-0065123-g004}

10.1371/journal.pone.0065123.t004

###### Stratified analyses of the miR-499A\>G (rs3746444) polymorphism and cancer risk.

![](pone.0065123.t004){#pone-0065123-t004-4}

  Variables             n[a](#nt113){ref-type="table-fn"}                      GG vs AA                       GA vs AA   GG+GA vs AA                       GG vs AA+GA                        G allele vs A allele                                                                                                                                                                                                                    
  -------------------- ----------------------------------- ------------------------------------------------- ---------- ------------- ------------------------------------------------------ ---------------------- ------ ------------------------------------------------------ ------- ------ ------------------------------------------------------ ------- ------ ------------------------------------------------------ ------- ------
  Total                                13                                 **1.25(1.03,1.52)**                  0.073        39.1       **1.28(1.08,1.53)** [c](#nt115){ref-type="table-fn"}          0.000           71.1   **1.27(1.08.1.50)** [c](#nt115){ref-type="table-fn"}   0.000   69.4     1.07(0.80,1.44)[c](#nt115){ref-type="table-fn"}      0.013   52.8   **1.18(1.04,1.34)** [c](#nt115){ref-type="table-fn"}   0.000   65.7
  Cancer type                                                                                                                                                                                                                                                                                                                                                                                                                         
  HCC                                   3                   1.25(0.36,4.34)[c](#nt115){ref-type="table-fn"}    0.023        73.6                         1.00(0.76,1.31)                             0.074           61.6     1.12(0.63,1.99)[c](#nt115){ref-type="table-fn"}      0.009   78.8                     1.51(0.87,2.62)                      0.062   64.0     1.13(0.64,2.01)[c](#nt115){ref-type="table-fn"}      0.001   85.0
  Breast cancer                         2                                   1.50(0.98,2.30)                    0.157        50.0         1.57(0.83,2.95)[c](#nt115){ref-type="table-fn"}             0.044           75.4                   **1.31(1.09,1.57)**                    0.182   43.8     0.97(0.29,3.19)[c](#nt115){ref-type="table-fn"}      0.019   81.7                   **1.26(1.08,1.47)**                    0.760   0.0
  Other cancers                         8                                   1.14(0.90,1.44)                    0.334        12.3       **1.32(1.05,1.67)** [c](#nt115){ref-type="table-fn"}          0.000           76.7   **1.29(1.05,1.59)** [c](#nt115){ref-type="table-fn"}   0.001   73.0                     1.02(0.81,1.28)                      0.092   43.0   **1.18(1.02,1.37)** [c](#nt115){ref-type="table-fn"}   0.006   64.9
  Country                                                                                                                                                                                                                                                                                                                                                                                                                             
  China                                 6                   1.54(0.93,2.56)[c](#nt115){ref-type="table-fn"}    0.029        59.8       **1.36(1.06,1.75)** [c](#nt115){ref-type="table-fn"}          0.002           74.0   **1.40(1.08,1.82)** [c](#nt115){ref-type="table-fn"}   0.000   77.9   **1.41(1.06,1.87)** [c](#nt115){ref-type="table-fn"}   0.050   54.8   **1.36(1.07,1.72)** [c](#nt115){ref-type="table-fn"}   0.000   79.8
  Korea                                 2                                   0.81(0.41,1.59)                    0.366         0.0                         0.94(0.74,1.19)                             0.126           57.2                     0.93(0.74,1.17)                      0.098   63.5                     0.83(0.42,1.62)                      0.461   0.0                      0.93(0.76,1.14)                      0.103   62.4
  North India                           3                                   1.02(0.70,1.50)                    0.439         0.0         1.46(0.95,2.22)[c](#nt115){ref-type="table-fn"}             0.038           69.4                   **1.33(1.07,1.66)**                    0.150   47.3                     0.83(0.58,1.18)                      0.110   54.6                     1.13(0.96,1.33)                      0.726   0.0
  Other countries                       2                                   1.27(0.82,1.97)                    0.293         9.5         1.44(0.62,3.35)[c](#nt115){ref-type="table-fn"}             0.010           85.0                     1.14(0.91,1.41)                      0.059   72.0     0.91(0.32,2.58)[c](#nt115){ref-type="table-fn"}      0.040   76.3                     1.11(0.93,1.33)                      0.728   0.0
  Source of controls                                                                                                                                                                                                                                                                                                                                                                                                                  
  Population based                     11                                   1.17(0.94,1.44)                    0.115        35.4       **1.27(1.05,1.54)** [c](#nt115){ref-type="table-fn"}          0.000           68.5   **1.24(1.04,1.47)** [c](#nt115){ref-type="table-fn"}   0.002   64.8     0.98(0.71,1.34)[c](#nt115){ref-type="table-fn"}      0.027   50.6   **1.14(1.00,1.29)** [c](#nt115){ref-type="table-fn"}   0.012   56.1
  Hospital based                        2                                 **1.70(1.09,2.67)**                  0.121        58.3         1.35(0.70,2.58)[c](#nt115){ref-type="table-fn"}             0.002           89.5     1.43(0.76,2.69)[c](#nt115){ref-type="table-fn"}      0.002   89.9                   **1.67(1.07,2.61)**                    0.176   45.4     1.44(0.82,2.52)[c](#nt115){ref-type="table-fn"}      0.002   89.7

HCC: hepatocellular carcinoma.

Number of included studies.

*P* value of *Q* test for heterogeneity test.

Random-effect model was used when P value for heterogeneity \<0.05; otherwise, fixed-effect model was used.

Statistically significant results were in bold.

Overall Effects for Alleles {#s3c}
---------------------------

Allele comparisons were also conducted in this meta-analysis. For allele comparison of rs2910164 polymorphism, a decreased cancer risk was observed in C allele (OR = 0.92, 95% CI: 0.85--1.00, *Z* = 2.00, *P* = 0.046, *P* ~h~ = 0.000) for pooled analysis. In the subgroup analysis of cancer type, a decreased risk was observed in HCC (OR = 0.88, 95% CI: 0.78--1.00, *Z* = 1.99, *P* = 0.046, *P* ~h~ = 0.245) and cervical cancer (OR = 0.72, 95% CI: 0.62--0.84, *P* ~h~ = 0.796). Country subgroup analysis revealed C allele was associated with decreased cancer risk in Chinese population (OR = 0.87, 95% CI: 0.79--0.95, *P* ~h~ = 0.000). When stratified analysis by genotyping method, C allele was associated with obvious decreased cancer risk by Taqman (OR = 0.84, 95% CI: 0.76--0.92, *P* ~h~ = 0.570).

There was no evidence that rs11614913 T allele associated with the risk of cancer. Meanwhile we conducted subgroup analysis of cancer type, country, source of controls and genotyping method. In the subgroup analysis of cancer type, a decreased risk was observed in CRC (OR = 0.84, 95% CI: 0.76--0.92, *P* ~h~ = 0.281) and lung cancer (OR = 0.87, 95% CI: 0.80--0.95, *P* ~h~ = 0.854). Country subgroup analysis revealed T allele was associated with decreased cancer risk in Korean population (OR = 0.87, 95% CI: 0.79--0.96, *P* ~h~ = 0.608). In the subgroup analysis of genotyping method indicated a decreased cancer risk with T allele determined by Taqman (OR = 0.87, 95% CI: 0.77--0.98, *P* ~h~ = 0.191).

For rs3746444 polymorphism, a significant increased cancer risk was found in the population with G allele (OR = 1.18, 95% CI: 1.04--1.34, *P* ~h~ = 0.000). In addition, cancer type subgroup analysis G allele was associated with increased breast cancer (OR = 1.26, 95% CI: 1.08--1.47, *P* ~h~ = 0.760) and other cancers (OR = 1.18, 95% CI: 1.02--1.37, *P* ~h~ = 0.006) risk. In the subgroup analysis of country, obvious increased cancer risk was observed in Chinese population (OR = 1.36, 95% CI: 1.07--1.72, *P* ~h~ = 0.000). Meanwhile, borderline increased cancer risk was observed in population- based controls with G allele (OR = 1.14, 95% CI: 1.00--1.29, *Z* = 1.98, *P* = 0.047, *P* ~h~ = 0.012).

Test of Heterogeneity {#s3d}
---------------------

For overall studies, there were significant heterogeneity observed in rs2910164, rs11614913 and rs3746444 polymorphisms. The source of the heterogeneity was evaluated for dominant model comparison by subgroups (cancer, country, source of controls and genotyping method). For rs2910164 polymorphism, the test revealed country (*χ^2^* = 11.64, df = 4, *P* = 0.020) but not cancer type (*χ^2^* = 11.03, df = 5, *P* = 0.051), source of controls (*χ^2^* = 0.05, df = 1, *P* = 0.832) and method (*χ^2^* = 4.54, df = 2, *P* = 0.103) contributed to substantial heterogeneity. For rs11614913 polymorphism, cancer type (*χ^2^* = 36.27, df = 5, *P* = 0.000) and country (*χ^2^* = 16.54, df = 3, *P* = 0.001) but not source of controls (*χ^2^* = 0.36, df = 1, *P* = 0.550) and genotyping method (*χ^2^* = 7.59, df = 3, *P* = 0.055) were found to contribute to substantial heterogeneity. For rs3746444 polymorphism, the source of heterogeneity was not observed in all subgroups.

Sensitivity Analysis {#s3e}
--------------------

Sensitivity analysis was performed to assess the stability of the results and assess the source of the heterogeneity by sequential removal of individual eligible study. For rs2910164 polymorphism, studies by Okubo [@pone.0065123-Okubo1] and Tian [@pone.0065123-Tian1] were the main origin of heterogeneity. The heterogeneity was decreased when these two studies removed (CC+GC vs GG: *P* ~h~ = 0.067, *I* ^2^ = 34.9%). For rs11614913 polymorphism, sensitivity analysis indicated that studies by Chu [@pone.0065123-Chu1], Dou [@pone.0065123-Dou1], George [@pone.0065123-George1] and Srivastava [@pone.0065123-Srivastava1] were the main origin of heterogeneity. The heterogeneity was decreased when these four studies removed (TT+CT vs CC: *P* ~h~ = 0.054, *I* ^2^ = 38.4%). For rs3746444 polymorphism, sensitivity analysis indicated that studies by Tian [@pone.0065123-Tian1], Chu [@pone.0065123-Chu1], Kim [@pone.0065123-Kim1] and Okubo [@pone.0065123-Okubo1] were the main origin of heterogeneity. The heterogeneity was decreased when these four studies removed (GG+GA vs AA: *P* ~h~ = 0.066, *I* ^2^ = 45.4%). In addition, no other single study was observed to impact the pooled OR by sensitivity analysis.

Publication Bias {#s3f}
----------------

Begg's funnel plot and Egger's test were performed to assess the publication bias of enrolled literature. The shape of the funnel plot indicated obvious asymmetry in rs11614913 dominant model comparison ([Figure 5A](#pone-0065123-g005){ref-type="fig"}). Thus, Egger's test was used to provide statistical evidence of funnel plot asymmetry (*t* = 2.15, *P* = 0.045) (shown in [Table 5](#pone-0065123-t005){ref-type="table"}), which suggested the existence of publication bias in this meta-analysis. To adjust this bias, a trim-and-fill method illustrated by Duval and Tweedie [@pone.0065123-Duval1] was utilized ([Figure 5B](#pone-0065123-g005){ref-type="fig"}). As a result, the conclusion with or without the trim-and-fill method did not change, which indicated that our results were statistically robust. While all models of rs2910164 and rs3746444 didn't show any publication bias (*P*\>0.05) (shown in [Table 5](#pone-0065123-t005){ref-type="table"}).

![Begg's funnel plot of Egger's test for publication bias test for rs.\
Each *circle* represents as an independent study for the indicated association. Log\[OR\], natural logarithm of OR. *Horizontal lines* mean effect size. A: Begg's funnel plot of publication bias test. B : Begg's funnel plot of publication bias test after trim-and-fill method.](pone.0065123.g005){#pone-0065123-g005}
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###### Egger's test for three polymorphisms of miRNAs.

![](pone.0065123.t005){#pone-0065123-t005-5}

  Polymorphism    Egger\'s test   Homozygote   Heterozygote   Dominant    Recessive
  -------------- --------------- ------------ -------------- ----------- -----------
  rs11614913           *t*           0.44          1.81         2.15        −0.92
                       *P*          0.662         0.086       **0.045**     0.369
  rs2910164            *t*           0.08          0.32         0.39        −0.32
                       *P*          0.939         0.755         0.700       0.753
  rs3746444            *t*          −0.36          1.86          1.6        −0.55
                       *P*          0.727         0.089         0.138       0.590

Statistically significant results which means the shape of the funnel plot indicated obvious asymmetry were in bold.

Discussion {#s4}
==========

As we all know, the association between the SNPs in protein-coding genes and the risk of cancer has been explained thoroughly, little cancer association studies concerning miRNA SNPs have been reported. In the present case-control study, associations of three miRNA polymorphisms (miR-146aG\>C, rs2910164;miR-196a2C\>T, rs11614913; miR-499A\>G, rs3746444;) and cancer susceptibility were estimated. The polymorphisms of these three miRNAs may influence the effect of their targets, which contributed to the tumorigenesis, development and prognosis of many cancers. It is believed that tumor necrosis factor receptor-associated factor 6 and interleukin-1 receptor-associated kinase 1 are two potential targets of miR-146a [@pone.0065123-Taganov1], which could decrease the levels of these two proteins and reduce the activity of the NF-κB signaling pathway involving in tumorigenesis [@pone.0065123-Punj1]. The main targets of miR-196a2 are homeobox (HOX) gene cluster and Annexin A1 (ANXA1). HOX genes include HOXB8, HOXC8, HOXD8, and HOXA7, which are known regulators of oncogenesis [@pone.0065123-Wynter1]. Meanwhile, ANXA1 is known as a mediator of apoptosis and an inhibitor of cell proliferation [@pone.0065123-Yang1]. MiR-499 mainly targets to transcriptional repressor SOX6 [@pone.0065123-Sluijter1], which reduce the level of fibroblast growth factor (FGF)-3 affecting cell proliferation and differentiation [@pone.0065123-Murakami1], [@pone.0065123-Jakobovits1]. In this meta-analysis, 31 eligible studies were enrolled to assess the association between three miRNA polymorphisms and cancer risk. We demonstrated that rs2910164 C allele, rs3746444 A allele and rs11614913 TT genotype were associated with significantly decreased risk of cancer.

Former studies regarding G to C variation in the miR-146a precursor showed that G-allelic miR-146a precursor displayed increased production of mature miR-146a compared with C-allelic and G allele in rs2910164 was associated with the predisposition of several cancers [@pone.0065123-Xu1], [@pone.0065123-Jazdzewski1], [@pone.0065123-Lung1]. In overall pooled results from 21 studies, we concluded rs2910164 C allele was associated with decreased cancer risk. Furthermore, stratified analyses by cancer type revealed that rs2910164 CC genotype reduced risk of HCC, cervical cancer and prostate cancer, however no significant associations were observed in breast cancer and gastric cancer, which indicated that rs2910164 polymorphism might have different effects in distinct cancers. The results were consistent with the previous studies [@pone.0065123-Hu1], [@pone.0065123-Xu1], [@pone.0065123-Zhou2], [@pone.0065123-Xu2]. While disaccords appeared in gastric cancer [@pone.0065123-Okubo1], [@pone.0065123-Zeng1], [@pone.0065123-Zhou3]. Inconsistent results might be caused by limited studies enrolled in this meta-analysis. Different study design and approach to select participants should also be taken into account. Followed stratified analyses by country indicated decreased cancer risk were discovered only in Chinese population, which reflected differences in genetic background and the environment exposured might produce different effects on cancer risk. At last, source of controls and genotyping method stratified analyses were also conducted in this meta-analysis. The results showed that different sources and methods could play different roles in cancer risk. As age and gender are risk factors for many cancers, which must be considered in this meta-analysis. The study conducted by Zeng et al [@pone.0065123-Zeng1] concluded that rs2910164 GG+GC genotype among males and subjects aged≤58 years was associtated with increased gastric cancer risk. The similar phenomenon was observed in the study by Zhou et al [@pone.0065123-Zhou3], which showed elevated gastric cancer risk was more evident among younger subjects (\<65 years) with rs2910164 GG genotype. However, they observed no significant difference in the stratification of sex. As age increases, accumulated exposure to environmental carcinogens and genomic alterations would facilitate carcinogenesis [@pone.0065123-Zhou3]. Therefore, the age is believed to be an important risk factor for cancers, which was inconsistent with our results. More genomic alterations and environmental carcinogens may contribute to late-onset gastric cancer and stratification analysis by age should be more cautious. As for the pre-miR-146a sex-specific effect, the exact mechanism remains unclear. Therefore, well-designed, unbiased, large case-control studies were urgently needed to achieve a more accurately result.

Recently, rs11614913 polymorphism in pre-miRNAs has been reported to contribute to susceptibility of breast cancer [@pone.0065123-Hu1], lung cancer [@pone.0065123-Tian1], glioma [@pone.0065123-Dou1], and influence survival of non-small cell lung cancer [@pone.0065123-Hu2] by altering the expression of mature miR-196a and its binding to target mRNA. Our results showed that TT genotype was associated with decreased risk of CRC, breast cancer and lung cancer, which was consistent with previous findings [@pone.0065123-Zhu1], [@pone.0065123-Alshatwi1], [@pone.0065123-Zhan1], [@pone.0065123-Hong1]. The controversy between our study were also apparent, no correlations were achieved between rs11614913 polymorphism and susceptibility of HCC and gastric cancer, while Li et al [@pone.0065123-Li1] and Okubo et al [@pone.0065123-Okubo1] presented contrary opinions respectively. In addition, contrast to Chinese and Korean population, rs11614913 CT genotype trend to increase cancer risk in North Indian population. Based on the above points, we deduced that cancer type and country differences made rs11614913 polymorphism have distinct effects. Cancer was a complex disease, and numerous factors would lead to tumorigenesis. Meanwhile, different cancers had different pathogenesis. Therefore, rs11614913 polymorphism might have distinct effects according to cancer types. Inconsistent results about different countries might be caused by differences in living habit, genetic background and the environment. In addition, this meta-analysis enrolled only 21 studies for rs11614913 polymorphism, inadequate study would be an influence factor. At the same time, the results also showed that different sources and methods contributed to different cancer risk. To further reveal the association between rs11614913 polymorphism and cancer risk, more well-designed studies based on homogeneous cancer patients and unbiased larger sample sizes were wanted.

As for rs3746444 G allele, an increased cancer risk was discovered in the pooled analysis. And subgroup analyses of cancer type and country showed that rs3746444 G allele association with increased risks were observed in breast cancer and Chinese population respectively. Meanwhile, a significant association was also observed for comparison of GG+GA vs AA in North Indian population. The results suggested different cancer types and countries could lead to distinct effects of rs3746444 polymorphism. Hu et al [@pone.0065123-Hu1] showed that significantly increased breast cancer risk was associated with variant genotypes of hsa-mir-499 rs3746444 in Chinese women, which consistent with our results. Finally,source of controls stratified analysis was also conducted. The results indicated distinct source of controls was also an important influence factor to affect the association between rs3746444 polymorphism and cancer risk. However, the results were based on 13 studies enrolled in the analysis, which could affect the results owing to small amount of studies. To draw a more precise conclusion, more related studies needed.

According to the test of heterogeneity conducted above, it's not difficult to perceive different countries contributed to heterogeneity of rs11614913 and rs2910164 polymorphisms, which indicated miRNAs might play different roles according to countries. Meanwhile, different cancer types were also a main factor contributed to heterogeneity. Significantly decreased associations were found mainly in HCC, lung cancer, cervical cancer, which suggested miRNAs might have different affections in different cancer types.

After all, this meta-analysis still existed some limitations. Firstly, publication bias which we have detected in rs11614913 polymorphism, and in other polymorphisms publication bias might also exist while we didn't detect owing to quantitative restrictions of studies. Secondly, there was no uniform definition of controls, although most of the controls were mainly selected from healthy populations, a few of them were patients. Thirdly, the detailed information (such as age, sex, menstrual history, life-style and environmental factors) was not considered so that our unadjusted estimates should be confirmed by further studies.

In conclusion, this meta-analysis measured the association of three miRNA polymorphisms and cancer risk. We observed TT genotype of rs11614913 polymorphism was associated with decreased cancer risk, especially for CRC and lung cancer in Korean and North Indian population. Moreover, rs2910164 C allele was associated with decreased overall cancer risk especially for HCC, cervical cancer and prostate cancer risk in Chinese population. Whereas, rs3746444 G allele was a risk factor in Chinese population, especially for breast cancer. However, further studies based on larger, stratified population to facilitate evaluation the association between miRNAs and cancer risk.
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